Harpoon Therapeutics (NASDAQ:HARP)' shares witnessed a significant surge of 39% to $9.57 on Monday, following the promising results of the Phase 1/2 clinical trial evaluating HPN328. The drug, developed from Harpoon's Tri-specific T cell Activating Construct platform, targets delta-like ligand 3 to combat small cell lung cancer and other neuroendocrine tumors.
The data cut-off on Sept. 12 revealed that HPN328 was generally well tolerated across all dose cohorts, including the 1 mg priming dose cohorts. There were no dose-limiting toxicities reported and the target maximum tolerated dose has not yet been achieved. Despite adverse events in 67 patients, a confirmed response rate of 35% was observed across all tumor types.
Harpoon Therapeutics plans to finalize the recommended Phase 2 regimen soon. The company also intends to launch registration studies in multiple tumor types in 2024. The success of the Phase 1/2 clinical trial and the subsequent rise in Harpoon's share value underscores the potential of HPN328 and its role in treating small-cell lung cancer and other neuroendocrine tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.